These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3752978)

  • 1. Frequency of aminoglycoside 6'-N-acetyltransferase among Serratia species during increased use of amikacin in the hospital.
    Larson TA; Garrett CR; Gerding DN
    Antimicrob Agents Chemother; 1986 Jul; 30(1):176-8. PubMed ID: 3752978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of bactericidal effects of four aminoglycoside antibiotics: amikacin, gentamicin, kanamycin and tobramycin (author's transl)].
    Drugeon HB; Courtieu AL
    Ann Microbiol (Paris); 1979 Apr; 130A(3):331-43. PubMed ID: 114083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center.
    Gerding DN; Larson TA
    Am J Med; 1985 Jul; 79(1A):1-7. PubMed ID: 4025364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985.
    Gerding DN; Larson TA
    Am J Med; 1986 Jun; 80(6B):22-8. PubMed ID: 3089003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tobramycin, amikacin, sissomicin, and gentamicin resistant Gram-negative rods.
    Drasar FA; Farrell W; Maskell J; Williams JD
    Br Med J; 1976 Nov; 2(6047):1284-7. PubMed ID: 1000196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S; Vera D; Ramírez-Ronda CH
    Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
    Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antibacterial activity of amikacin towards gentamicin-resistant, Gram-negative bacilli].
    Nicoletti G; Russo G; Toscano MA; Gismondo MR
    Boll Ist Sieroter Milan; 1979 Jan; 57(6):713-7. PubMed ID: 121911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of an aminoglycoside resistance plasmid by Serratia marcescens during treatment of meningitis with amikacin.
    Rubens CE; McGee ZA; Farrar WE
    J Infect Dis; 1980 Mar; 141(3):346-50. PubMed ID: 6988523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gentamicin-resistant Serratia marcescens endophthalmitis.
    Gammon JA; Schwab I; Joseph P
    Arch Ophthalmol; 1980 Jul; 98(7):1221-3. PubMed ID: 6994702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of netilmicin compared with gentamicin, tobramycin, amikacin, and kanamycin.
    Eickhoff TC; Ehret JM
    Antimicrob Agents Chemother; 1977 May; 11(5):791-6. PubMed ID: 879733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria.
    Moellering RC; Wennersten C; Kunz LJ; Poitras JW
    Am J Med; 1977 Jun; 62(6):873-81. PubMed ID: 868901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antimicrobial effectiveness of sisomicin. I: In vitro activity of sisomicin compared with gentamicin, tobramycin, amikacin and kanamycin (author's transl)].
    Schassan HH
    Infection; 1976; 4(2):35-41. PubMed ID: 789246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the resistance mechanisms of gentamicin-resistant Gram-negative bacilli and their susceptibility to tobramycin, netilmicin and amikacin.
    Maes P
    J Antimicrob Chemother; 1985 Mar; 15(3):283-9. PubMed ID: 3997704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro aminoglycoside resistance of gram-negative bacilli and staphylococci isolated from blood in Sweden 1980-1984.
    Bengtsson S; Bernander S; Brorson JE; Dornbusch K; Forsgren A; Hallander H; Henning C; Holm S; Malmborg AS; Nilsson L
    Scand J Infect Dis; 1986; 18(3):257-63. PubMed ID: 3738436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a chromosomal site specifying amikacin resistance in multiresistant Serratia marcescens.
    John JF; McNeill WF; Price KE; Kresel PA
    Antimicrob Agents Chemother; 1982 Apr; 21(4):587-91. PubMed ID: 7044303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of Sch 21420, derivative of gentamicin B, compared to that of amikacin.
    Kabins SA; Nathan C
    Antimicrob Agents Chemother; 1978 Nov; 14(5):786-7. PubMed ID: 727766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of resistance to kanamycin, tobramycin, netilmicin, and amikacin in gentamicin-resistant gram-negative bacteria.
    Seligman SJ
    Antimicrob Agents Chemother; 1978 Jan; 13(1):70-3. PubMed ID: 626492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
    Ruiz-Palacios GM; Ponce de Leon S; Sifuentes J; Ponce de Leon S; Calva JJ; Huazano F; Ontiveros C; Ojeda F; Bobadilla M
    Am J Med; 1986 Jun; 80(6B):71-5. PubMed ID: 3089006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital.
    Gerding DN; Larson TA; Hughes RA; Weiler M; Shanholtzer C; Peterson LR
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1284-90. PubMed ID: 1929283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.